Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Size: px
Start display at page:

Download "Empire BlueCross BlueShield Professional Commercial Reimbursement Policy"

Transcription

1 Subject: Frequency Editing NY Policy: 0016 Effective: 03/01/ /30/2016 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria listed below. DESCRIPTION The Health Plan uses claims processing logic based on ClaimsXten rationale to determine when the use of multiple units is appropriate. The Health Plan also uses, among other factors, the nomenclature for a particular Current Procedural Terminology (CPT ) or Healthcare Common Procedure Coding System (HCPCS Level II) code or the ability to clinically perform or report a particular service more than one time on a single date of service or within a particular date span per member per provider in making these determinations. POLICY 1. All or any of the following factors identify when a procedure will be limited in units, or number of times a code is eligible for reimbursement on a single date of service. a. The description of a procedure code includes the word(s) bilateral or unilateral or bilateral b. A procedure code description specifies unilateral and there is another CPT code for the bilateral service or another add-on code for additional services (the unilateral CPT code cannot be submitted more than once on a single date of service) c. The description of a procedure code includes a specified time frame (e.g. per 30 day period) d. The description of a procedure code implies multiplicity (e.g. evaluation(s); muscle(s); injection(s); area(s); material(s); etc.) e. The total number of times it is clinically possible or clinically reasonable to perform a given procedure on a single date of service is limited In some circumstances a RT/LT or site specific modifier ( e.g. F5, T3; etc.) will allow a code to process when used more than once, since these modifiers will identify the specific side or digit when more than one site is being treated or evaluated. f. A procedure code is reported more than one time, but typically is not performed more than once on a single date of service. 2. When a procedure code is submitted with multiple units, and only a single unit is acceptable, reimbursement will be based on only one unit. 3. The Health Plan will apply all unit/frequency edits pre-adjudication, using both the unit field and multiple submissions of line items. NY 0001 Page 1 of [12]

2 4. The Health Plan will apply a frequency edit, when applicable, to a base code which has a related addon code listed in CPT Appendix D. Since the related add-on code(s) describes a phrase such as each additional or list separately in addition to the primary procedure, the base code is eligible for reimbursement only once per date of service (e.g., only one of the following initial vaccine administration codes or is allowed per date of service.) 5. The Health Plan will apply some frequency edits across dates of service. 6. For Durable Medical Equipment (DME), the Health Plan will apply frequency maximums per day and/or per date span (usually based on the Centers for Medicare & Medicaid Services (CMS s) Medically Unlikely Edits (MUEs), industry standards, and/or HCPCS description). (See also our Durable Medical Equipment reimbursement policy.) 7. The Health Plan will apply some frequency maximums per day and/or per date span when procedures are within the same service grouping (e.g., routine blood collection on the same date of service will be allowed once per date of service; unattended sleep studies and/or home sleep studies reported on the same date of service and/or within a seven day period will only be allowed one time during the seven day period;). The Health Plan has customized ClaimsXten unit/frequency logic for some procedure codes. Please see the table in the Coding Section for these customizations. CODING The following occurrence restrictions are examples of some frequency edits added to certain codes that do not fit into one of the categories identified in the policy section above, or the description of the code includes a designated time frame. Services billed in excess of these restrictions are not eligible for reimbursement even when billed with an override modifier (e.g., modifier 59 or modifier 91). The inclusion or exclusion of a specific code does not indicate eligibility for coverage under all circumstances Debridement of nail(s) by any method(s); 1 to 5 1 per 60 days** frequency limit includes and NY 0001 Page 2 of [12]

3 1 per 60 days** Debridement of nail(s) by any method(s); 6 or more frequency limit includes and Collection of venous blood by venipuncture ** frequency limit includes 36415, , Collection of capillary blood specimen (eg, finger, heel, ear stick) Ultrasonic guidance for needle placement (e.g., biopsy, aspiration, injections, localization device), imaging supervision and interpretation Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid) Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision and interpretation Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan Hyperthermia, externally generated; superficial (i.e., heating to a depth of 4 cm or less) or deep (i.e., heating to depths greater than 4 cm) 36416, and S9529 ** frequency limit includes 36415, 36416, and S9529 NY 0001 Page 3 of [12]

4 80320 Definitive drug testing: Alcohols 80321, Definitive drug testing: Alcohol biomarkers Definitive drug testing: Alkaloids, not otherwise specified 80324, 80325, Definitive drug testing: Amphetamines , Definitive drug testing: Anabolic steroids 80329, 80330, Definitive drug testing: Analgesics, non-opioid , 80333, Definitive drug testing: Antidepressents, serotonergic class 80335, 80336, Definitive drug testing: Antidepressants, tricyclic and other cyclicals , 80340, , 80343, Definitive drug testing: Antidepressants, not otherwise specified Definitive drug testing: Antiepileptics, not otherwise specified Definitive drug testing: Antipsychotics, not otherwise specified Definitive drug testing: Barbiturates 80346, Definitive drug testing: Benzodiazepines Definitive drug testing: Buprenorphine Definitive drug testing: Cannabinoids, natural 80350, 80351, Definitive drug testing: Cannabinoids, synthetic Definitive drug testing: Cocaine Definitive drug testing: Fentanyl NY 0001 Page 4 of [12]

5 80355 Definitive drug testing: Gabapentin, non-blood Definitive drug testing: Heroin metabolite Definitive drug testing: Ketamine and norketamine Definitive drug testing: Methadone Definitive drug testing: Methylenedioxyamphetamines (MDA, MDEA, MDMA) Definitive drug testing: Methylphenidate Definitive drug testing: Opiates 80362, 80363, Definitive drug testing: Opioids and opiate analogs Definitive drug testing: Oxycodone Definitive drug testing: Phencyclidine (PCP) Definitive drug testing: Pregabalin Definitive drug testing: Propoxyphene , Definitive drug testing: Sedative hypnotics (non-benzodiazepines) Definitive drug testing: Skeletal muscle relaxants Definitive drug testing: Stimulants, synthetic Definitive drug testing: Tapentadol Definitive drug testing: Tramadol NY 0001 Page 5 of [12]

6 Definitive drug testing: Stereoisomer (enantiomer) analysis, single drug class 80375, 80376, Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified Unlisted molecular pathology procedure Level IV Surgical pathology, gross and microscopic examination needle biopsy prostate Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each 9 units per date of service when reported for specimens related to needle biopsy of the prostrate 4 per date of service Fundus photography with interpretation and report 93268, 93270, Wearable patient activated EKG event recording 93271, per 30 day period of time 93293, 93294, Transtelephonic rhythm strip pacemaker 93295, evaluation(s) system up to 90 days 1 per 90 days 93297, 93298, Implantable cardiovascular monitor system, interrogation device evaluation(s) up to 30 days Doppler echocardiography color flow velocity mapping 2 per date of service 94014, 94015, Patient-initiated spirometric recording per day period of time 94774, 94775, Pediatric home apnea monitoring event 94776, recording per 30 day period of time 95250, Continuous glucose monitoring Professional services for the supervision of 120 doses per preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses) Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and 1 per 7 days ** NY 0001 Page 6 of [12]

7 sleep time frequency limit includes 95800, 95801, 95806, G0398, G0399, and G , 96151, 96152, 96153, Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone) Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement) Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist s or physician s time, both face-toface time with the patient and time interpreting test results and preparing the report Health and behavior assessment/intervention; each 15 minutes 1 per 7 days ** frequency limit includes 95800, 95801, 95806, G0398, G0399, and G per 7 days ** frequency limit includes 95800, 95801, 95806, G0398, G0399, and G hours/units per 8 per date of service Additional sequential infusion, up to 1 hour 6 per date of service Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic Initiation of prolonged IV Chemotherapy administration (more than 8 hours) requiring the use of a portable or implantable pump for the administration of drugs such as omalizumab (Xolair ), per drug NY 0001 Page 7 of [12]

8 97012,97014, 97016, 97018, 97022,97024, Physical medicine modalities 97026, Physician attendance and supervision of hyperbaric oxygen therapy, per session 3 per date of service 99363, Anticoagulant management 90 days of therapy 1 per 90 days 0403T Preventive behavior change, intensive program\of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day and 24 per A4210 Needle-free injection device, each 2 per A4230 Infusion set for external insulin pump, non needle cannula type 60 per 90 days A4231 Infusion set for external insulin pump, needle type 60 per 90 days A4232 Syringe with needle for external insulin pump, sterile, 3CC 60 per 90 days A4244 Alcohol or peroxide, per pint 12 per 90 days A4245 Alcohol wipes, per box 24 per 90 days A4250 Urine test or reagent strips or tablets (100 tablets or strips) 4 per 90 days A4253 Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips 13 per 90 days A4257 Replacement lens shield cartridge for use with laser skin piercing device, each A4258 Spring-powered device for lancet, each 2 per A4259 Lancets, per box of per 90 days A4556 Electrodes per pair 2 pair per 30 days (See also our Bundled Services and Supplies reimbursement policy for additional information.) A4557 Lead wires per pair 4 pair per (See also our Bundled Services and Supplies reimbursement policy NY 0001 Page 8 of [12]

9 A4595 A6530 A6531 A6532 A6533 A6534 A6535 A6536 A6537 A6538 A6539 A6540 A6541 A6545 A6549 for additional information.) E0441, E0442, E0443, E0444 E1812 Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES) Gradient compression stocking, below knee, mm Hg, each Gradient compression stocking, below knee, mm Hg, each Gradient compression stocking, below knee, mm Hg, each Gradient compression stocking, thigh length, mm Hg, each Gradient compression stocking, thigh length, mm Hg, each Gradient compression stocking, thigh length, mm Hg, each Gradient compression stocking, full-length/chap style, mm Hg, each Gradient compression stocking, full-length/chap style, mm Hg, each Gradient compression stocking, full-length/chap style, mm Hg, each Gradient compression stocking, waist length, mm Hg, each Gradient compression stocking, waist length, mm Hg, each Gradient compression stocking, waist length, mm Hg, each Gradient compression wrap, nonelastic, below knee, mm Hg, each Gradient compression stocking/sleeve, not otherwise specified Oxygen one month s supply Dynamic knee, extension/flexion device, include soft interface material 2 per 30 days 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per 8 per NY 0001 Page 9 of [12]

10 G0249 Provision of test materials and equipment for home INR monitoring includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests 3 per 90 days Home sleep study test (HST) with type II 1 per 7 days ** G0398 portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, frequency limit includes 95800, airflow, respiratory effort and oxygen saturation 95801, 95806, G0398, G0399, and G0400 G0399 G0400 Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation] Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels 1 per 7 days ** frequency limit includes 95800, 95801, 95806, G0398, G0399, and G per 7 days ** frequency limit includes 95800, 95801, 95806, G0398, G0399, and G0400 G0431 Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter G0434 Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test or moderate complexity test, per patient encounter J0129 Orencia, 10 mg 100 per date of service J0585 Botox / Botox cosmetic, 1 unit 600 per date of service J0586 Dysport, 5 units 200 per date of service NY 0001 [12] Page 10 of

11 J0696 Injection, ceftriaxone sodium, per 250 mg (Rocephin) 16 per date of service J0717 Cimzia, 1 mg 400 per date of service J0897 Prolia/Xgeva, 1 mg 120 per date of service J1453 Fosaprepitant (Emend), 1 mg 150 per date of service J1560 Injection, gamma globulin, intramuscular, over 10cc J1750 Iron dextran, 50 mg 20 per date of service J2353 Octreotide, depot form for intramuscular injection, (Sandostatin, depot) 1 mg 40 per date of service J2357 Injection, omalizumab, 5 mg (Xolair) 90 per 14 days J2469 Injection, palonosetron HCl, 25 mcg (Aloxi) 10 per date of service J2505 Injection, pegfilgrastim, 6 mg (Neulasta) J2507 Pegloticase (Krystexxa), 1 mg 8 per date of service J2800 Injection, methocarbamol, up to 10 ml (Robaxin) 3 per date of service J3489 Zoledronic acid, 1 mg 5 per date of service J7307 Etonogestrel (contraceptive) implant system (Implanon; Nexplanon) J7312 Dexamethasone, intravitreal implant (Ozurdex), 0.1 mg 14 per 90 days J7321, J7323, Hyaluronan or derivative for intra-articular J7324, J7326 injection, per dose 2 per date of service J7325 Hyaluronan or derivative (Synvisc or Synvisc- One), 1 mg 96 per date of service J9031 BCG (intravesical) per instillation (Theracys/Tice Bcg) J9047 Carfilzomib (Kyprolis), 1 mg 60 per date of service J9202 Goserelin acetate implant (Zoladex), per 3.6 mg 3 per date of service J9217 Leuprolide acetate (for depot suspension), 7.5 mg (Lupron Depot, Eligard) 6 per date of service NY 0001 [12] Page 11 of

12 J9355 Injection, trastuzumab, 10 mg (Herceptin ) 95 units per date of service J9395 Fulvestrant (Faslodex), 25 mg 20 per date of service Q4101 Apligraf, per sq cm 44 per date of service S9123 Nursing care, in the home; by registered nurse, per hour 24 per date of service S9124 Nursing care, in the home; by licensed practical nurse, per hour 24 per date of service S9529 Routine venipuncture for collection of specimen(s), single homebound, nursing home, or skilled nursing facility patient ** frequency limit includes 36415, 36416, and S CPT is a registered trademark of the American Medical Association Use of Reimbursement Policy: State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over Reimbursement Policy and must be considered first in determining eligibility for coverage. The member s contract benefits in effect on the date that services are rendered must be used. Reimbursement Policy is constantly evolving and we reserve the right to review and update these policies periodically Empire BlueCross BlueShield No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Empire BlueCross BlueShield. NY 0001 [12] Page 12 of

Empire BlueCross BlueShield Professional Reimbursement Policy

Empire BlueCross BlueShield Professional Reimbursement Policy Subject: Frequency Editing NY Policy: 0016 Effective: 05/01/2015 08/16/2015 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria

More information

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy Subject: Frequency Editing NY Policy: 0016 Effective: 01/01/2017 02/28/2017 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria

More information

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy Subject: Frequency Editing NY Policy: 0016 Effective: 03/01/2017 04/30/2017 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria

More information

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy Subject: Frequency Editing NY Policy: 0016 Effective: 05/01/2017 05/19/2017 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria

More information

Anthem Blue Cross and Blue Shield Commercial Professional Reimbursement Policy

Anthem Blue Cross and Blue Shield Commercial Professional Reimbursement Policy Subject: Frequency Editing CT Policy: 0016 Effective: 03/01/2017 03/31/2017 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria

More information

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Payment Policy: Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each

More information

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 04/10/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each

More information

MEDICAL POLICY No R2 DRUG TESTING

MEDICAL POLICY No R2 DRUG TESTING Summary of Changes MEDICAL POLICY DRUG TESTING Effective Date: April 10, 2017 Review Dates: 5/15, 5/16, 11/16, 2/17 Date Of Origin: May 13, 2015 Status: Current Clarifications: Deletions: Additions: Pg.

More information

Clinical Drug Screening and/or Drug Testing

Clinical Drug Screening and/or Drug Testing Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 5/3/2018

More information

Clinical Drug Screening and/or Drug Testing

Clinical Drug Screening and/or Drug Testing Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 3/6/2017

More information

Anthem Blue Cross and Blue Shield Commercial Professional Reimbursement Policy

Anthem Blue Cross and Blue Shield Commercial Professional Reimbursement Policy Subject: Laboratory and Venipuncture Services ME Policy: 0029 Effective: 08/22/2016 03/31/2017 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products

More information

UniCare Professional Reimbursement Policy

UniCare Professional Reimbursement Policy UniCare Professional Reimbursement Policy Subject: Laboratory and Venipuncture Services Policy #: UniCare 0029 Adopted: 02/02/2010 Effective: 08/31/2017 Coverage is subject to the terms, conditions, and

More information

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or Integrated Reference #: MP/D010 Page: 1 of 7 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services,

More information

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy Subject: Documentation Guidelines for Central Nervous System Assessments and Tests NY Policy: 0046 Effective: 12/01/2014 11/30/2015 Coverage is subject to the terms, conditions, and limitations of an individual

More information

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009 STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines

More information

Disclosures. Get Your Specimens in Order:

Disclosures. Get Your Specimens in Order: Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Jennifer Bolen, JD Disclosures Jennifer Bolen, JD Consultant to Generation Partners Consultant to Abbott

More information

Anthem Central Region Clinical Claims Edit

Anthem Central Region Clinical Claims Edit Please compare the claim's date of adjudication to the range of the edit in question. Prior versions, if any, can be found below. Subject: Different Services with Anesthesia Services Edit #785 Effective

More information

Ultrasound Reimbursement Guide 2015: BioJet Fusion

Ultrasound Reimbursement Guide 2015: BioJet Fusion Ultrasound Reimbursement Guide 2015: BioJet Fusion Diagnosis codes explain the rationale for a given service and are a key factor in a payer s evaluation of medical necessity and coverage determination

More information

Sleep Management Program Changes: Frequently Asked Questions for Providers

Sleep Management Program Changes: Frequently Asked Questions for Providers Sleep Management Program Changes: Frequently Asked s for Providers New Sleep Studies Program Managed by NIA General What is changing? Harvard Pilgrim is updating our authorization program for both attended

More information

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: March 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: March 1, Related Policies None DRUG TESTING POLICY UnitedHealthcare Oxford Reimbursement Policy Policy Number: ADMINISTRATIVE 259.3 T0 Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE LINES OF

More information

Routine Venipuncture and/or Collection of Specimens

Routine Venipuncture and/or Collection of Specimens Manual: Policy Title: Reimbursement Policy Routine Venipuncture and/or Collection of Specimens Section: Laboratory & Pathology Subsection: None Date of Origin: 1/1/2000 Policy Number: RPM012 Last Updated:

More information

2015 Annual Physician Notice

2015 Annual Physician Notice 0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the

More information

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None DRUG TESTING POLICY UnitedHealthcare Oxford Reimbursement Policy Policy Number: ADMINISTRATIVE 259.2 T0 Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE LINES

More information

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None DRUG TESTING POLICY UnitedHealthcare Oxford Reimbursement Policy Policy Number: ADMINISTRATIVE 259.1 T0 Effective Date: October 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE LINES

More information

Coding for Preventive Services A Guide for HIV Providers

Coding for Preventive Services A Guide for HIV Providers Coding for Preventive Services A Guide for HIV Providers Jessie Murphy, MPH and Michelle Cataldo, LCSW, April 2016 Implementation of the Patient Protection and Affordable Care Act and other regulatory

More information

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee Reimbursement Policy CMS 1500 Drug Testing Policy Policy Number 2017R6005A Annual Approval Date 05/10/2017 Approved By Reimbursement Policy Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY

More information

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: PA.CP.MP.50

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: PA.CP.MP.50 Clinical Policy: Reference Number: PA.CP.MP.50 Effective Date: 01/18 Last Review Date: 09/17 Coding Implications Revision Log Description Urine drug testing is a key diagnostic and therapeutic tool that

More information

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-47 Effective Date: 07/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Drug Testing Policy. Approved By 05/10/2017. Application This reimbursement policy applies to UnitedHealthcare Community Plan Medicaid products.

Drug Testing Policy. Approved By 05/10/2017. Application This reimbursement policy applies to UnitedHealthcare Community Plan Medicaid products. Policy Number 2017R6005B Annual Approval Date Drug Testing Policy 05/10/2017 Approved By Reimbursement Policy Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY You are responsible for

More information

DME NO AUTHORIZATION REQUIRED LIST October 1st, 2012 Revision. ALL PROVIDERS (Vendors, Home Health, Offices)

DME NO AUTHORIZATION REQUIRED LIST October 1st, 2012 Revision. ALL PROVIDERS (Vendors, Home Health, Offices) DME NO AUTHORIZATION REQUIRED LIST October 1st, 2012 Revision For members who have Medicare Part B fee-for-service, no authorization is needed for any Part B covered service! Contracted vendors must be

More information

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee Reimbursement Policy CMS 1500 Drug Testing Policy Policy Number 2018R6005A Annual Approval Date 07/11/2018 Approved By Reimbursement Policy Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY

More information

MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE

MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE UnitedHealthcare Commercial Utilization Review Guideline MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE Guideline Number: URG-13.01 Effective Date: February 1, 2019 Table

More information

CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT. Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE

CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT. Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE Phone: 800-609-1108 Email: codmanpump@aol.com Fax: 303-703-1572

More information

Lumify. Lumify reimbursement guide {D DOCX / 1

Lumify. Lumify reimbursement guide {D DOCX / 1 Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing

More information

AAHAM Western Region December 11, 2014

AAHAM Western Region December 11, 2014 Chargemaster Changes for 2015 AAHAM Western Region December 11, 2014 Presented by: Terrance Wong Terrance Wong & Associates Healthcare Financial Consultants 350 Augusta Drive Palm Desert, CA 92211 (760)

More information

Drug Testing Policy. Approved By 06/14/2017

Drug Testing Policy. Approved By 06/14/2017 Drug Testing Policy Policy Number Annual Approval Date 06/14/2017 Approved By Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare Medicare Advantage

More information

Ultrasound Reimbursement Information for Anesthesiology 1

Ultrasound Reimbursement Information for Anesthesiology 1 GE Healthcare Ultrasound Reimbursement Information for Anesthesiology 1 January, 2009 www.gehealthcare.com/reimbursement This overview addresses coding, coverage, and for ultrasound guidance with continuous

More information

Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians

Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians GE Healthcare Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians January, 2013 www.gehealthcare.com/reimbursement This overview

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

Clinical Breast Examination N/A Yes Screening Mammogram $ TC $ 43.56

Clinical Breast Examination N/A Yes Screening Mammogram $ TC $ 43.56 For the Period 07/01/2015 through 06/30/2016 Revised: 10/09/2015 Breast Procedures (1) Screening Clinical Breast Examination N/A Screening Mammogram 77057 $ 78.38 77057-TC $ 43.56 77057-26 $ 34.82 Follow-Up

More information

Coding Companion for Podiatry. A comprehensive illustrated guide to coding and reimbursement

Coding Companion for Podiatry. A comprehensive illustrated guide to coding and reimbursement Coding Companion for Podiatry comprehensive illustrated guide to coding and reimbursement 2016 Contents Contents Foot and Toes 28043-28045 [28039, 28041] 28043 28039 28045 28041 Excision, tumor, soft tissue

More information

Sympathetic Electrical Stimulation Therapy for Chronic Pain

Sympathetic Electrical Stimulation Therapy for Chronic Pain Sympathetic Electrical Stimulation Therapy for Chronic Pain Policy Number: 015M0076A Effective Date: April 01, 015 RETIRED 5/11/017 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION COVERAGE

More information

Medicare CPAP/BIPAP Coverage Criteria

Medicare CPAP/BIPAP Coverage Criteria Medicare CPAP/BIPAP Coverage Criteria For any item to be covered by Medicare, it must 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment

More information

Sleep 101. Kathleen Feeney RPSGT, RST, CSE Business Development Specialist

Sleep 101. Kathleen Feeney RPSGT, RST, CSE Business Development Specialist Sleep 101 Kathleen Feeney RPSGT, RST, CSE Business Development Specialist 2016 Why is Sleep Important More than one-third of the population has trouble sleeping (Gallup) Obstructive Sleep Apnea Untreated

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

FY16 BCCS Reimbursement Rates and Billing Guidelines Appendix B 2

FY16 BCCS Reimbursement Rates and Billing Guidelines Appendix B 2 FY16 BCCS Reimbursement Rates and Billing Guidelines Appendix B 2 77053 Mammary ductogram or galactogram, single duct, Global Fee $59.05 May be billed with 77055, G0206, 77056, G0204, 76641, 76642 Billable

More information

2017 Drug Screen Tests

2017 Drug Screen Tests 2017 Drug Screen Tests The ABCs of Applying the CMS 2017 HCPCS Codes Written by: Karen D. Chappell, EJD, MBA, CIRCC, CPMA, CPC-I, CHC Terminology Immunoassay Qualitative Therapeutic Quantitative GC/MS

More information

Diabetes Management, Equipment and Supplies

Diabetes Management, Equipment and Supplies Coverage Summary Diabetes Management, Equipment and Supplies Policy Number: D-001 Products: UnitedHealthcare Medicare Advantage Plans Original Approval Date: 11/01/2006 Approved by: UnitedHeatlhcare Medicare

More information

Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Vascular Procedures 1

Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Vascular Procedures 1 GE Healthcare Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Vascular Procedures 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage,

More information

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: PA.CP.MP.50

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: PA.CP.MP.50 Clinical Policy: Reference Number: PA.CP.MP.50 Effective Date: 01/18 Last Review Date: 09/18 Coding Implications Revision Log Description Urine drug testing is a key diagnostic and therapeutic tool that

More information

Reimbursement Information for Ultrasound-guided Procedures Performed by Anesthesiologists 1

Reimbursement Information for Ultrasound-guided Procedures Performed by Anesthesiologists 1 GE Healthcare Information for Ultrasound-guided Procedures Performed by Anesthesiologists 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage, and payment for ultrasound

More information

The following are J Code requirements

The following are J Code requirements The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based

More information

INDIANA HEALTH COVERAGE PROGRAMS

INDIANA HEALTH COVERAGE PROGRAMS INDIANA HEALTH COVERAGE PROGRAMS PROVIDER CODE TABLES Note: Due to possible changes in Indiana Health Coverage Programs (IHCP) policy or national coding updates, inclusion of a code on the code tables

More information

Physical Therapy and Occupational Therapy Initial Evaluation and Reevaluation Reimbursement Policy. Approved By

Physical Therapy and Occupational Therapy Initial Evaluation and Reevaluation Reimbursement Policy. Approved By Policy Number Physical Therapy and Occupational Therapy Initial Evaluation and Reevaluation Reimbursement Policy 0044 Annual Approval Date 4/2017 Approved By Optum Reimbursement Committee Optum Quality

More information

Cigna - Prior Authorization Procedure List: Radiology & Cardiology

Cigna - Prior Authorization Procedure List: Radiology & Cardiology Cigna - Prior Authorization Procedure List: Radiology & Cardiology Category CPT Code CPT Code Description 93451 Right heart catheterization 93452 Left heart catheterization 93453 Combined right and left

More information

Clinical Policy: Outpatient Testing for Drugs of Abuse

Clinical Policy: Outpatient Testing for Drugs of Abuse Clinical Policy: Reference Number: CP.MP.50 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description

More information

2017 NBCCEDP Allowable Procedures and Relevant CPT Codes

2017 NBCCEDP Allowable Procedures and Relevant CPT Codes 2017 NBCCEDP Allowable Procedures and Relevant CPT Codes Listed below are allowable procedures and the corresponding suggested Current Procedural Terminology (CPT) codes for use in the National Breast

More information

Clinical UM Guideline

Clinical UM Guideline Clinical UM Guideline UniCare Health Plan of West Virginia, Inc. Medicaid Managed Care December 2018 Subject: Drug Testing or Screening in the Context of Substance Use Disorder and Chronic Pain Guideline

More information

CARE ABOUT YOUR HEALTH

CARE ABOUT YOUR HEALTH WE CARE ABOUT YOUR HEALTH THE REVOLUTION OF MEDICINE DO IT YOURSELF US FDA 510(k)OTC Cleared/Exempt CLIA Waived FERTILITY TESTS SPEED ACCURACY EXCELLENCE HCG PREGNANCY TEST HLH OVULATION TEST* HFSH MENOPAUSE

More information

WPS Medicare Part B - Quarterly CERT Error Findings Report ~ MICHIGAN ~

WPS Medicare Part B - Quarterly CERT Error Findings Report ~ MICHIGAN ~ WPS Medicare Part B - Quarterly CERT Error Findings Report ~ MICHIGAN ~ This report provides details of Comprehensive Error Rate Testing (CERT) errors assessed July 2014 through September 2014 for Michigan

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

MEDICAL MANAGEMENT POLICY

MEDICAL MANAGEMENT POLICY PAGE: 1of 8 This Medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage, the employer/member summary

More information

Anesthesia Processing Guidelines

Anesthesia Processing Guidelines Anesthesia Processing Guidelines Policy Number: 10.01.511 Last Review: 5/2018 Origination: 10/1988 Next Review: 5/2019 Policy The following guidelines are utilized in processing anesthesia claims: 1) Anesthesia

More information

Name of Policy: Sympathetic Therapy and Bioelectrical Nerve Block or Electroanalgesic Nerve Block for the Treatment of Pain

Name of Policy: Sympathetic Therapy and Bioelectrical Nerve Block or Electroanalgesic Nerve Block for the Treatment of Pain Name of Policy: Sympathetic Therapy and Bioelectrical Nerve Block or Electroanalgesic Nerve Block for the Treatment of Pain Policy #: 015 Latest Review Date: February 2010 Category: Therapy Policy Grade:

More information

Foundational funding sources allow BCCHP to screen and diagnose women outside of the CDC guidelines under specific circumstances in Washington State.

Foundational funding sources allow BCCHP to screen and diagnose women outside of the CDC guidelines under specific circumstances in Washington State. Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for breast cancer. The program is funded through a grant from the Centers for Disease Control and Prevention

More information

2015 Procedure Billing Codes Update

2015 Procedure Billing Codes Update 2015 Procedure Billing Codes Update COURSE DESCRIPTION Important Update! This learning activity consists of questions about new, deleted, and revised 2015 CPT procedure billing codes. The lists of new,

More information

2018 Cerebrovascular Reimbursement Coding Fact Sheet

2018 Cerebrovascular Reimbursement Coding Fact Sheet The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Cordis Corporation concerning levels of reimbursement, payment,

More information

CERT PAP Errors: The DME CERT Outreach and Education Task Force Responds

CERT PAP Errors: The DME CERT Outreach and Education Task Force Responds CERT PAP Errors: The DME CERT Outreach and Education Task Force Responds DME CERT Outreach and Education Task Force National PAP Webinar, December 17, 2014 PAP CERT Errors Medical Records: Face-to-Face

More information

2012 CPT Changes Affecting Radiology REVISIONS

2012 CPT Changes Affecting Radiology REVISIONS 2012 CPT Changes Affecting Radiology REVISIONS 22520 Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection; thoracic 22521 lumbar 22522

More information

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide.

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide. DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide The information in this presentation is a general overview on using Confirm BioSciences DrugConfirm Advanced urine drug test cup; however,

More information

Modifier SL - State Supplied Vaccine

Modifier SL - State Supplied Vaccine Manual: Policy Title: Reimbursement Policy Modifier SL - State Supplied Vaccine Section: Modifiers Subsection: None Date of Origin: 6/26/2007 Policy Number: RPM024 Last Updated: 8/7/2017 Last Reviewed:

More information

DrugConfirm Advanced Urine Dip Cards.

DrugConfirm Advanced Urine Dip Cards. DrugConfirm Advanced Urine Dip Cards The information in this presentation is a general overview on using the Confirm BioSciences DrugConfirm Advanced drug test cup but can be applied to many similarly

More information

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

Claims Edit Guideline: Drug Testing

Claims Edit Guideline: Drug Testing Applicable To: Medicaid Medicare Claims Edit Guideline: Drug Testing Policy Number: Original Effective Date: 12/5/2013 Revised Date(s): 5/1/2014; 5/22/2015, 12/16/2015 BACKGROUND CMS has seen a dramatic

More information

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea

More information

ICD-9-CM Diagnosis Code options

ICD-9-CM Diagnosis Code options ICD-9-CM Diagnosis Code options Diagnosis codes are used by both physicians and facilities to document the indication for the procedure. Intrathecal drug delivery is directed at managing chronic, intractable

More information

2019 ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule

2019 ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule This document and the information contained herein is for general information purposes only and is not intended and does not constitute legal, reimbursement,

More information

Cardiac Rhythm Management Coder 2017

Cardiac Rhythm Management Coder 2017 Cardiac Rhythm Management Coder 2017 An easy-to-use tool for coding and reimbursement compliance Prepared and Published By: MedLearn Publishing, A Division of Panacea Healthcare Solutions, Inc. 287 East

More information

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90 Clinical Policy: Reference Number: CP.MP.90 Effective Date: 01/18 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082 Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending

More information

Ultrasound and Fluoroscopic Paravertebral Facet Joint Injections

Ultrasound and Fluoroscopic Paravertebral Facet Joint Injections Policy Number FAC06222011RP Ultrasound and Fluoroscopic Approved By UnitedHealthcare Medicare Committee Current Approval Date 06/25/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable

More information

Powering Efficient Behavioral Health Care Services

Powering Efficient Behavioral Health Care Services Powering Efficient Behavioral Health Care Services Streamlining behavioral health care decisions through comprehensive and efficient drug monitoring Quest Diagnostics has you and your patients covered

More information

Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION

Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION IMPORTANT: St. Jude Medical provides this reference guide for general information purposes only

More information

2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE

2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE 2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE Contents Overview of Central Venous Access s for Hemodialysis 2 Procedures Using Hemodialysis s 2 Physician Reimbursement for Hemodialysis s 3

More information

Coding for Sleep Disorders Jennifer Rose V. Molano, MD

Coding for Sleep Disorders Jennifer Rose V. Molano, MD Practice Coding for Sleep Disorders Jennifer Rose V. Molano, MD Accurate coding is an important function of neurologic practice. This section of is part of an ongoing series that presents helpful coding

More information

CHAP 11.doc Version 15.3

CHAP 11.doc Version 15.3 CHAP 11.doc CHAPTER XI MEDICINE EVALUATION AND MANAGEMENT SERVICES CPT CODES 90000-99999 FOR NATIONAL CORRECT CODING INITIATIVE POLICY MANUAL FOR MEDICARE SERVICES Current Procedural Terminology 2008 American

More information

Timed Therapeutic Procedures

Timed Therapeutic Procedures Timed Therapeutic Procedures Policy Number: 10.01.526 Last Review: 4/2014 Origination: 4/2009 Next Review: 4/2015 Policy Documentation to support the reporting of timed procedure codes is required. The

More information

2019 MITRACLIP CODING AND PAYMENT GUIDE

2019 MITRACLIP CODING AND PAYMENT GUIDE CLAIM 2019 MITRACLIP AND PAYMENT GUIDE MitraClip Transcatheter Mitral Valve Repair Hospital Rates: Effective October 1, 2018 Physician Rates: Effective January 1, 2019 References and Brief Summary 1 CLAIM

More information

Reimbursement Information for Diagnostic Musculoskeletal Ultrasound and Ultrasound-guided Procedures 1

Reimbursement Information for Diagnostic Musculoskeletal Ultrasound and Ultrasound-guided Procedures 1 GE Healthcare Reimbursement Information for Diagnostic Musculoskeletal Ultrasound and Ultrasound-guided Procedures 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage,

More information

Family Planning Eligibility Program

Family Planning Eligibility Program INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2

More information

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

PREFACE TO THE IMAGING GUIDELINES Version 17.0; Effective

PREFACE TO THE IMAGING GUIDELINES Version 17.0; Effective evicore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for patients with atypical symptoms or clinical presentations

More information

Cigna - Prior Authorization Procedure List Cardiology

Cigna - Prior Authorization Procedure List Cardiology Cigna - Prior Authorization Procedure List Cardiology Category CPT Code CPT Code Description 33206 Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial 33207 Insertion

More information

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT INFUSION SERVICES & EQUIPMENT Effective Date: August 1, 2017 Review Dates: 10/95, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 10/07, 10/08, 10/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 2/16, 2/17, 5/17

More information

FY 2015 BCCCP Procedure Code Reference Chart

FY 2015 BCCCP Procedure Code Reference Chart Procedure Reference Chart 77057 G0202 77055 G0206 77056 G0204 Screening mammography, bilateral (two view film study of each breast) Screening mammography producing direct digital image, bilateral, all

More information

High Tech Imaging Quick Reference Guide

High Tech Imaging Quick Reference Guide High Tech Imaging Quick Reference Guide 1 High Tech Imaging Authorizations may now be requested through our secure provider portal, BlueAccess. Getting Started Step 1: Log into BlueAccess from www.bcbst.com

More information

The revision date appears in the footer of the document. Links within the document are updated as changes occur throughout the year.

The revision date appears in the footer of the document. Links within the document are updated as changes occur throughout the year. An Independent Licensee of the Blue Cross Blue Shield Association. APPENDIX C HOME INFUSION THERAPY MANUAL This appendix to the Business Procedure Manual briefly describes home infusion therapy benefits

More information

Dental Policy. Subject: Prophylaxis Guideline #: Publish Date: 03/15/2018 Status: Revised Last Review Date: 02/06/2018

Dental Policy. Subject: Prophylaxis Guideline #: Publish Date: 03/15/2018 Status: Revised Last Review Date: 02/06/2018 Dental Policy Subject: Prophylaxis Guideline #: 01-101 Publish Date: 03/15/2018 Status: Revised Last Review Date: 02/06/2018 Description This document addresses the procedure of dental prophylaxis for

More information

Cardiac Rhythm Management Coder 2018

Cardiac Rhythm Management Coder 2018 Cardiac Rhythm Management Coder 2018 An easy-to-use tool for coding and reimbursement compliance Prepared and Published By: MedLearn Publishing, A Division of MedLearn Media, Inc. 445 Minnesota Street,

More information